You are here

Press Releases

Vascular Dynamics, Inc. today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD® device for the treatment of resistant hypertension.

Geneva Health Solutions (formerly Geneva Healthcare) announced it raised $1.9 million to expand its Cardiac Remote Monitoring Solutions business to cardiology providers to help manage patients with implanted cardiac devices beyond the walls of the practice.

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases

SCAI Envisions Bright Future with Francesca Dea, Who Brings More Than 20 Years of Experience

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has closed its acquisition of Valtech Cardio Ltd

Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the world, affecting more than 12% of the world’s population, according to the World Health Organization.

 Dr. Joseph Lamelas, an internationally recognized expert in minimally invasive heart surgery, has joined the Michael E. DeBakey Department of Surgery at Baylor College of Medicine as associate chief of cardiac surgery in the division of cardiothoracic surgery.

Building on European success, leading remote patient monitoring company expands to the USA to provide local support following substantial interest in its solutions

Medical device expert will help secure the development of the medical robotics start-up against the backdrop of robust growth in the cardiovascular market

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Marc Semigran, M.D., has joined the Company as chief medical officer. In his new position, Dr. Semigran will oversee clinical development and lead MyoKardia’s clinical trial strategy.

MISSISSAUGA, Ontario, Nov. 14, 2016 /PRNewswire/ --Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced new data for YOSPRALA™, a recently FDA-approved prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), demonstrated significantly lower rates of gastric and duodenal ulcers compared to aspirin alone among patients with a history of myocardial infarction at risk for secondary cardiovascular events and gastrointestinal problems related to aspirin therapy at the annual American Heart Association Scientific Sessions.

SOUTH JORDAN, Utah, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it has received 510(k) clearance for the SwiftNINJA™ Steerable Microcatheter.  The clearance covers peripheral and coronary applications. With the exception of Japan, Merit has global distribution rights for the SwiftNINJA.

WASHINGTON—The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the Congenital Cardiac Anesthesia Society (CCAS), today published recommendations for institutions and physicians diagnosing and treating pediatric patients in the catheterization laboratory. This first-of-its-kind document titled, “SCAI/CCAS/SPA Expert Consensus Statement for Anesthesia and Sedation Practice: Recommendations for Patients Undergoing Diagnostic and Therapeutic Procedures in the Pediatric and Congenital Cardiac Catheterization Laboratory,” is published in Catheterization and Cardiovascular Interventions, the official journal of SCAI.

IRVINE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2016.

ROCHESTER, N.Y., Nov. 2 — Carestream will show its DRX-Revolution Nano Mobile X-ray System (INVESTIGATIONAL-Not available for commercial sale) at the Radiological Society of North America conference (Booth #4704). This fully integrated DR portable imaging system will offer a compact design with an articulating arm and rotation column, small footprint, and carbon nanotube technology that significantly reduces weight. 

REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- biotricity, Inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has appointed Dr. Rony Shimony to its Board of Advisors (BOA). Shimony is an internationally recognized clinical cardiologist who brings to the company over twenty-five years of experience in cardiac patient care and related technology.

DURHAM, NC – October 28, 2016 – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, and Cardinal Health, a global integrated healthcare services and products company, today announced that the companies have established a long-term strategic agreement for U.S. distribution of the Tryton Side Branch Stent, pending regulatory approval.

DUBLIN and HYDERABAD, India - Oct. 27, 2016 - In recognition of World Stroke Day, Medtronic plc (NYSE:MDT) and the World Stroke Organization (WSO) joined together for the third year to raise awareness of stroke and discuss the Road Map for Quality Stroke Care at a press conference held today at the World Stroke Congress in Hyderabad, India.

SAN CARLOS, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s Tempo® Lead, an innovative temporary pacing lead designed for use in procedures in which temporary pacing is indicated, including transcatheter aortic valve replacement (TAVR) and electrophysiology (EP) procedures.

WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that an overview of the Company’s Phase 1 clinical program of investigational vonapanitase in peripheral artery disease (PAD) will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, in Washington, DC.

Pages